Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AVI-4126 Injection (RESTEN-NG®)
AVI-4126 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AVI-4126 Injection (RESTEN-NG®) | DRUG | - |
Inclusion Criteria: * Adult males 18 years to 64 years of age; * Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) * Signed and dated written informed consent form; and * Willing to partici...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
AVI-4126 is an investigational small molecule developed by Sarepta Therapeutics, Inc. (ticker SRPT) for neoplasms in oncology. It is also known as AVI-4126 Injection (RESTEN-NG). It has been studied in a single Phase 1 clinical trial and is not approved for any indication.
AVI-4126 has been studied in oncology for neoplasms. Its only recorded clinical trial enrolled healthy male volunteers aged 18 years and older in the United States, so the work to date has focused on early pharmacokinetic evaluation rather than treatment of patients with cancer.
AVI-4126 is developed by Sarepta Therapeutics, Inc., which trades under the ticker SRPT. Sarepta is the sponsor associated with the drug's clinical program in oncology.
AVI-4126 is in Phase 1 development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
AVI-4126 has been evaluated in one completed Phase 1 trial, NCT00343148, titled "Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG) in Cerebral Spinal Fluid." It enrolled 6 participants in the United States and was an uncontrolled study without randomization or blinding.
Yes. AVI-4126 is also known as AVI-4126 Injection (RESTEN-NG). RESTEN-NG is the alternate name used for the same investigational agent, including in the title of its completed Phase 1 pharmacokinetic trial, NCT00343148.